Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached

The big biotech’s blinatumomab gains accelerated approval to treat a rare form of ALL. The breakthrough therapy does have a REMS on serious risks and administration concerns.